Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Study ID
- NCT02963402
- Status
- Completed
Conditions
- Arthritis,Rheumatoid
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tocilizumab — DRUG
- Adalimumab — DRUG
Study Details
We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.
Key Dates
- Start date
- Nov 9, 2016
- Status verified
- Nov 2018
- Primary completion
- Oct 1, 2018
- Completion
- Oct 1, 2018
Study Design
- Enrollment
- 35 participants (actual)
Arms
- Arm: Tocilizumab treated
- Arm: Anti-TNF treated
Primary Outcome Measure
Treg phenotype [ Time Frame: Baseline to 6 months change ]